Better Therapeutics Inc Share Price Today: Live Updates & Key Insights

Better Therapeutics Inc share price today is $0.036, up 27.43%. The stock opened at $0.0716 against the previous close of $0.035, with an intraday high of $0.095 and low of $0.0423.

Better Therapeutics Inc Share Price Chart

Better Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Better Therapeutics Inc Share Price Performance

$0.036 0.2743(27.43%) BTTX at 23 Mar 2026 12:20 PM Biotechnology
Lowest Today 0.0423
Highest Today 0.095
Today’s Open 0.0716
Prev. Close 0.035
52 Week High 1.61
52 Week Low 0.03
Day’s Range: Low 0.0423 High 0.095
52-Week Range: Low 0.03 High 1.61
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -
5 year return -
10 year return -

Better Therapeutics Inc Institutional Holdings

Mmcap International Inc. Spc 2.90

Vanguard Group Inc 0.92

Vanguard Institutional Extnd Mkt Idx Tr 0.36

Geode Capital Management, LLC 0.20

BlackRock Inc 0.16

Fidelity Extended Market Index 0.15

Capital Investment Advisory Services, LLC 0.13

Fidelity Nasdaq Composite Index 0.13

State Street Corporation 0.11

BlackRock Extended Mkt Composite 0.10

BlackRock Extended Equity Market K 0.09

Millennium Management LLC 0.07

iShares Micro-Cap ETF 0.05

CI Private Wealth LLC 0.05

Citadel Advisors Llc 0.05

Tower Research Capital LLC 0.04

Group One Trading, LP 0.03

Northern Trust Corp 0.03

Ameriprise Financial Inc 0.03

XTX Topco Ltd 0.03

Fidelity Series Total Market Index 0.02

NT Ext Equity Mkt Idx Fd - NL 0.02

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.01

Northern Trust Extended Eq Market Idx 0.01

NT Ext Equity Mkt Idx Fd - L 0.01

Extended Equity Market Fund M 0.01

SSgA U.S. Extended Market Index Class I 0.01

State St US Extended Mkt Indx NL Cl C 0.01

Spartan Total Market Index Pool E 0.01

SSgA U.S. Total Market Index Strategy 0.00

1290 VT Micro Cap K 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

Aspire Private Capital, LLC 0.00

Royal Bank of Canada 0.00

Wells Fargo & Co 0.00

PSI Advisors, LLC 0.00

Farallon Capital Management, L.L.C. 0.00

JPMorgan Chase & Co 0.00

Better Therapeutics Inc Market Status

Strong Buy: 2

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Better Therapeutics Inc Fundamentals

Market Cap 1.91 M

PB Ratio 2.289

PE Ratio 0.0

Enterprise Value 9.67 M

Total Assets 22.94 M

Volume 204525202

Better Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:8000 0.0M, FY19:18000 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:-674000 -0.7M, FY19:-880000 -0.9M

Annual Net worth FY23:-31573000 -31.6M, FY22:-39760000 -39.8M, FY21:-40335000 -40.3M, FY20:-6387000 -6.4M, FY19:-5795000 -5.8M

Quarterly Revenue Q3/2023:0 0.0M, Q2/2023:0 0.0M, Q1/2023:0 0.0M, Q4/2022:0 0.0M, Q3/2022:0 0.0M

Quarterly Profit Q3/2023:null 0.0M, Q2/2023:null 0.0M, Q1/2023:null 0.0M, Q4/2022:null 0.0M, Q3/2022:null 0.0M

Quarterly Net worth Q3/2023:-5862000 -5.9M, Q2/2023:-7589000 -7.6M, Q1/2023:-9357000 -9.4M, Q4/2022:-8765000 -8.8M, Q3/2022:-11405000 -11.4M

About Better Therapeutics Inc & investment objective

Company Information Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Organisation Biotechnology

Employees 54

Industry Biotechnology

CEO Mr. Frank L. Karbe

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Better Therapeutics Inc FAQs

What is the share price of Better Therapeutics Inc today?

The current share price of Better Therapeutics Inc is $0.036.

Can I buy Better Therapeutics Inc shares in India?

Yes, Indian investors can buy Better Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Better Therapeutics Inc shares in India?

You can easily invest in Better Therapeutics Inc shares from India by:

Can I buy fractional shares of Better Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Better Therapeutics Inc?

Better Therapeutics Inc has a market cap of $1.91 M.

In which sector does Better Therapeutics Inc belong?

Better Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Better Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Better Therapeutics Inc?

The PE ratio of Better Therapeutics Inc is N/A and the PB ratio is 2.29.